![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1627937
Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ ½ÃÀå ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м®, ¿¹Ãø(2024-2032³â)Fluorescence Guided Surgery Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032 |
¼¼°èÀÇ Çü±¤ °¡ÀÌµå ¼ö¼ú ½Ã½ºÅÛ(FGS) ½ÃÀåÀº 2023³â¿¡ 1¾ï 130¸¸ ´Þ·¯ÀÇ Æò°¡¾×¿¡ ´ÞÇϸç, 2024-2032³â 14.1%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
FGS ½Ã½ºÅÛÀº Çü±¤Áõ¹éÁ¦·Î Á¶Á÷À» ±¸º°ÇÏ´Â ½Ç½Ã°£ ¿µ»óÀ» Á¦°øÇÔÀ¸·Î½á ¼ö¼úÀ» °ÈÇÏ¿© º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ ¼ö¼úÀ» Áö¿øÇÕ´Ï´Ù.
¼ö¼ú ÀÎÇÁ¶ó °È¿¡ ÃÊÁ¡À» ¸ÂÃá Á¤ºÎÀÇ ±¸»óÀº Çü±¤ À¯µµ ¼ö¼ú(FGS) ½Ã½ºÅÛ¿¡ ´ëÇÑ Å« ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ³ë·Â¿¡´Â ÀϹÝÀûÀ¸·Î ÷´Ü ÀÇ·á ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ, ½Ã¼³ ¾÷±×·¹À̵å, ¼ö¼úÀÇ Á¤È®¼º°ú °á°ú¸¦ Çâ»ó½ÃŰ´Â Çõ½ÅÀûÀÎ ÅøÀÇ »ç¿ë ÃËÁø µîÀÌ Æ÷ÇԵ˴ϴÙ. À̹ø º¸Á¶±ÝÀº ¿Â·ç¸ÞÀÇ FGS ½Ã½ºÅÛ °³¹ßÀ» Áö¿øÇϸç, ¼ö¼ú Áß Ç÷°ü ¹× ¼Ò¸²ÇÁ Á¶Á÷ÀÇ °¡½Ã¼ºÀ» °³¼±ÇÏ°í ±Ã±ØÀûÀ¸·Î ¼ö¼úÀÇ Á¤È®¼º°ú ȯÀÚ °á°ú¸¦ Çâ»ó½ÃŰ´Â Àåºñ¸¦ °³¼±ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå À¯Çüº°·Î´Â VS3 À̸®µã ½Ã½ºÅÛ, SPY ½Ã½ºÅÛ, PDE ½Ã½ºÅÛ, ±âŸ·Î ºÐ·ùµÇ¸ç, 2023³â¿¡´Â SPY ½Ã½ºÅÛ ºÎ¹®ÀÌ 38.1% ½ÃÀå Á¡À¯À²·Î ¼±µÎ¸¦ Â÷ÁöÇϸç CAGR 15%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °í±Þ À̹Ì¡°ú Á¤¹Ðµµ·Î À¯¸íÇÑ SPY ½Ã½ºÅÛÀº ICG Çü±¤ À̹Ì¡À» »ç¿ëÇÏ¿© Ç÷·ù¿Í Á¶Á÷ °ü·ù¸¦ ½Ã°¢ÈÇÏ¿© ¿Ü°ú Àǻ簡 Á¶Á÷ÀÇ »ýÁ¸ °¡´É¼ºÀ» Æò°¡ÇÏ°í ½Ç½Ã°£À¸·Î Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖµµ·Ï ÇÔÀ¸·Î½á ¼ö¼ú Á¤È®µµ¸¦ Çâ»ó½ÃŰ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.
½ÃÀå ¹üÀ§ | |
---|---|
°³½Ã³â | 2023 |
¿¹Ãø³â | 2024-2032 |
°³½Ã ±Ý¾× | 1¾ï 130¸¸ ´Þ·¯ |
¿¹Ãø ±Ý¾× | 3¾ï 3,070¸¸ ´Þ·¯ |
CAGR | 14.1% |
¿ëµµº°·Î ½ÃÀåÀº º¹°°æ/³»½Ã°æ ¼ö¼ú°ú °³º¹ ¼ö¼ú·Î ³ª´¹´Ï´Ù. °³º¹ ¼ö¼úÀº 2023³â 54.2%·Î °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇߴµ¥, ÀÌ´Â ÁÖ·Î º¹ÀâÇÏ°í ´ë±Ô¸ð ¼ö¼ú¿¡¼ FGS ½Ã½ºÅÛÀÌ Á¾¾ç°ú ÁÖº¯ Á¶Á÷À» ÀÚ¼¼È÷ º¼ ¼ö ÀÖÀ¸¸ç, ¾Ç¼º ¼¼Æ÷ÀÇ Á¤È®ÇÑ Á¦°Å¸¦ ¿ëÀÌÇÏ°Ô Çϰí ÀÜÁ¸ ÁúȯÀÇ À§ÇèÀ» ÃÖ¼ÒÈÇÒ ¼ö ÀÖ´Â °³º¹ ¼ö¼ú¿¡ ƯÈ÷ À¯¿ëÇÕ´Ï´Ù. ƯÈ÷ °³º¹¼ö¼ú¿¡ À¯¿ëÇÕ´Ï´Ù.
ºÏ¹Ì FGS ½ÃÀåÀº ¹Ì±¹ÀÌ ÁÖµµÇϰí ÀÖÀ¸¸ç, 2023³â 3,840¸¸ ´Þ·¯ÀÇ ¸ÅÃâÀ» ¿Ã·È½À´Ï´Ù. ÀÇ·á ±â¼ú Çõ½ÅÀÇ Áß½ÉÁöÀÎ ¹Ì±¹Àº ÷´Ü À̹Ì¡°ú »õ·Î¿î Çü±¤Á¦¸¦ »ç¿ëÇÏ´Â FGS ½Ã½ºÅÛÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¾ÏÀÇ ³ôÀº À¯º´·ü·Î ÀÎÇØ ¿Ü°ú ÀÇ»çµéÀÌ ¾î·Á¿î ¼ö¼úÀÇ Ä¡·á °á°ú¸¦ Çâ»ó½ÃŰ´Â ±â¼úÀ» ¿ì¼±½ÃÇϹǷΠFGS¿¡ ´ëÇÑ ¼ö¿ä°¡ ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
The Global Fluorescence Guided Surgery Systems Market reached a valuation of USD 101.3 million in 2023 and is projected to grow at a CAGR of 14.1% from 2024 to 2032. FGS systems enhance surgical procedures by providing real-time imaging that differentiates tissues with fluorescent dyes, supporting more precise and effective surgeries.
Government initiatives focused on enhancing surgical infrastructure are driving significant demand for fluorescence-guided surgery (FGS) systems. These initiatives typically involve investments in advanced medical technologies, facility upgrades, and encouraging the use of innovative tools that improve surgical precision and outcomes. The grant supports OnLume's development of its FGS system, aiming to refine the device for improved intraoperative visualization of blood vessels and small lymphatic tissues, ultimately enhancing surgical accuracy and patient results.
The market is categorized by type into VS3 Iridium systems, SPY systems, PDE systems, and others. In 2023, the SPY system segment led with a market share of 38.1% and is expected to grow at a 15% CAGR. Known for its advanced imaging and precision, the SPY system uses ICG fluorescence imaging to visualize blood flow and tissue perfusion essential for enhancing surgical accuracy by enabling surgeons to assess tissue viability and make informed decisions in real-time.
Market Scope | |
---|---|
Start Year | 2023 |
Forecast Year | 2024-2032 |
Start Value | $101.3 Million |
Forecast Value | $330.7 Million |
CAGR | 14.1% |
In terms of application, the market is divided into laparoscopic/endoscopic surgery and open surgery. Open surgery held the largest share in 2023 at 54.2%, largely due to its role in complex, extensive procedures. FGS systems are particularly beneficial in open surgeries, where they enable detailed visualization of tumors and adjacent tissues, facilitating precise removal of malignant cells and minimizing the risk of residual disease.
The U.S. dominated the North American FGS market, generating USD 38.4 million in revenue in 2023. As a hub for medical technology innovation, the U.S. leads in growth of FGS systems with advanced imaging and new fluorescent agents. The high prevalence of cancer further drives demand for FGS, as surgeons prioritize techniques that enhance outcomes in challenging surgeries.